Kate Knobil, M.D., was appointed Chief Medical Officer of GlaxoSmithKline in November 2017. Dr. Knobil previously served as CMO for Pharmaceuticals since November 2015, comprising Global Clinical Safety and Pharmacovigilance, Value Evidence and Outcomes (VEO), and the Medical Groups in the Respiratory and Specialty Franchises, as well as within Classic and Established Products. Together, these groups work together to understand the current and future needs of patients, clinicians and healthcare systems to generate and communicate evidence that informs on the benefits, risks, and overall value of our medicines. Previous to this role, Dr. Knobil was SVP, VEO with global accountability for delivering the evidence to support the value of GSK medicines for patients, healthcare providers, and payers. She also had responsibility for the Real World Evidence Strategy for GSK. Kate is a physician with extensive experience in pharmaceutical development. She completed her Fellowship in Pulmonary and Critical Care Medicine at the Johns Hopkins Medical School, where she obtained an NIH grant to study the regulation of inflammatory genes after influenza virus infection. She joined GSK in 1997 to lead clinical development in the US for Respiratory medicines. International assignments first took her to the UK in 2005 to lead the European Respiratory Clinical Team, and then to China in 2010 to build the late stage clinical development capability across therapy areas.